The first and only once-daily triple therapy in a single inhaler for adult patients with COPD or ASTHMA

DividerDivider

Only TRELEGY offers patients the simplicity of once-daily triple therapy in a single inhaler with uninterrupted 24-hour effect4-6

TRELEGY is the #1 PRESCRIBED
 single inhaler triple therapy*

ICS/LABA/LAMA

TRELEGY

ICS/LABA/LAMA

BREZTRI7

ICS/LABA

SYMBICORT8†
One Inhalation, Once a Day      
NO Priming or Shaking Required      
NO Routine Inhaler Cleaning Required      
NO Hand/Breath Coordination Required      
FDA-Approved for Both COPD and ASTHMA      
Flexible Dosing for ASTHMA—2 Strengths Available      
TRELEGY is the #1 PRESCRIBED single inhaler triple therapy*

ICS/LABA/LAMA

TRELEGY

ICS/LABA/LAMA

BREZTRI7

ICS/LABA

SYMBICORT8†

One Inhalation, Once a Day
 
 
 
NO Priming or Shaking Required
 
 
 
NO Routine Inhaler Cleaning Required
 
 
 
NO Hand/Breath Coordination Required
 
 
 
FDA-Approved for Both COPD and ASTHMA
 
 
 
Flexible Dosing for ASTHMA—2 Strengths Available
 
 
 

No comparative efficacy or safety conclusions can be drawn from this table.

*Based on IQVIA NPA Data as of December 2024.

† US formulation; metered-dose inhaler.

WHY WAIT to prescribe TRELEGY?

Simplified delivery: 3 medications. 1 inhaler. 1 daily inhalation.

Watch Now

How to Use the TRELEGY ELLIPTA Inhaler

This video demonstrates clearly how to take a dose of TRELEGY. Watch this video with your patients so they can learn how to use the inhaler.

Watch Video

Could once-daily triple therapy in a single inhaler make a difference for your patients?

 

According to the GOLD COPD Report:

  • Minimizing the number of different inhaler types is suggested for patients as using a single inhaler improves adherence9

 

According to the GINA ASTHMA Report:

  • Avoid the use of multiple different inhaler types where possible for ASTHMA as it may lead to confusion and poor adherence10

 

TRELEGY does not replace a rescue inhaler. Acute symptoms should be treated with an inhaled SABA.

TRELEGY for COPD 100/62.5/25 mcg

TRELEGY dosing considerations for patients with COPD or ASTHMA

 

Instruct ALL patients to:

  • Take TRELEGY ELLIPTA as 1 inhalation, once daily, at the same time every day
  • Use TRELEGY only once every 24 hours
  • After inhalation, rinse the mouth with water without swallowing to reduce the risk of oropharyngeal candidiasis
  • Treat acute symptoms with an inhaled SABA such as albuterol

 

No dosage adjustment is required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.

 

For patients with COPD:
TRELEGY 100/62.5/25 mcg is the only strength indicated for the treatment of COPD.

 

For patients with ASTHMA:

Either strength—100/62.5/25 mcg or 200/62.5/25 mcg—can be the starting dose.

 

When choosing the starting dose, consider:

  • Patients’ disease severity and their previous ASTHMA therapy, including the ICS dosage
  • Patients’ current control of ASTHMA symptoms and risk of future exacerbation

 

For patients who do not respond adequately to TRELEGY 100 once daily, increasing the dose to TRELEGY 200 once daily may provide additional improvement in ASTHMA control. Maximum recommended dosage is 1 inhalation of TRELEGY 200 once daily. For patients who do not respond adequately to TRELEGY 200 once daily, re-evaluate and consider other therapeutic regimens and additional therapeutic options.

 

For more details:

See Dosage and Administration in the full Prescribing Information.

 

 
 
 
 

ELLIPTA inhaler rated “easy to use”1-3

 

At the conclusion of two 4-week clinical studies, 1 in COPD and 1 in ASTHMA1-3:

 

93% of patients with COPD and 96% of patients with asthma

93% or patients with COPD1,3 & 96% of patients with asthma2,3

 

93% of patients with COPD and 96% of patients with asthma

Gray lungs icon

93% of patients with COPD and 96% of patients with asthma

 

Demonstrated correct use and rated the ELLIPTA inhaler easy to use1-3

 

Inhalers in study did not contain active ingredient.

 

Inhaler image is for illustrative purposes only.

     

     
     
     
     

    TRELEGY: 3 Complementary Mechanisms of Action

     

    Once-daily dosing with uninterrupted 24-hour effect4-6

    ICS11,12

    (fluticasone furoate)
    reduces inflammation

    ICS (fluticasone furoate) reduces inflammation

    LABA12,13

    (vilanterol)
    promotes bronchodilation

    LABA (vilanterol) promotes bronchodilation

    LAMA12,13

    (umeclidinium)
    inhibits bronchoconstriction

    LAMA (umeclidinium) inhibits bronchoconstriction

    Airway for illustrative purposes only.
    Image is not intended to represent actual effects of treatment.

    Role of LAMA

     

    Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic.

    The mechanism of LAMA in the airways is primarily attributed to blocking acetylcholine from binding to muscarinic receptors.

    Because LAMA works through a distinct complementary pathway from LABA, it can help increase bronchodilation beyond what may be achieved with a single bronchodilator.12,13

    See helpful resources for your patients.

     

    Explore resources

    Help your patients try TRELEGY.

     

    Request samples now

    Review Instructions for Use in Patient Information.

     

    Download now

    Explore the clinical data for once-daily TRELEGY in patients with COPD.

    Learn more

    INDICATIONS & IMPORTANT SAFETY INFORMATION

    INDICATIONS

    IMPORTANT SAFETY INFORMATION

    INDICATIONS

    • COPD: TRELEGY 100/62.5/25 is for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
    • Asthma: TRELEGY is for maintenance treatment of adults with asthma.

    Limitations of Use: TRELEGY is NOT for the relief of acute bronchospasm.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS

    TRELEGY is contraindicated in the following:

    • Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.
    • Patients with severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate (FF), umeclidinium (UMEC), vilanterol (VI), or any of the excipients.

    WARNINGS AND PRECAUTIONS

    • Long-acting beta2-adrenergic agonist (LABA) monotherapy for asthma increases the risk of asthma-related death, and in pediatric and adolescent patients, available data also suggest an increased risk of asthma-related hospitalization. These findings are considered a class effect of LABA monotherapy. When LABA are used in fixed-dose combination with inhaled corticosteroids (ICS), data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone. TRELEGY is not indicated for use in pediatric patients aged 17 years and younger.
    • TRELEGY should NOT be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD or asthma.
    • TRELEGY is NOT a rescue medication and should NOT be used for the relief of acute bronchospasm or symptoms. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.
    • TRELEGY should not be used more often or at higher doses than recommended or with another LABA for any reason, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs, like LABA.
    • Oropharyngeal candidiasis has occurred in patients treated with orally inhaled drug products containing fluticasone furoate. Advise patients to rinse their mouths with water without swallowing after inhalation.
    • Lower respiratory tract infections, including pneumonia, have been reported following use of ICS, like fluticasone furoate. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD, as clinical features of pneumonia and exacerbations frequently overlap.
    • A more serious or even fatal course of chickenpox or measles may occur in susceptible patients using corticosteroids. ICS should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.
    • Particular care is needed for patients transferred from systemic corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients during and after transfer. Taper patients slowly from systemic corticosteroids if transferring to TRELEGY.
    • Hypercorticism and adrenal suppression may occur with higher than the recommended dosage or at the regular dosage of ICS in susceptible individuals. If such changes occur, reduce the dose of TRELEGY slowly and consider other treatments for management of COPD or asthma symptoms.
    • Caution should be exercised when considering the coadministration of TRELEGY with ketoconazole and other known strong CYP3A4 inhibitors (including, but not limited to, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased systemic corticosteroid and cardiovascular adverse effects may occur.
    • If paradoxical bronchospasm occurs, discontinue TRELEGY and institute alternative therapy.
    • Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of TRELEGY. Discontinue TRELEGY if such reactions occur.
    • Vilanterol can produce clinically significant cardiovascular effects in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles. If such effects occur, TRELEGY may need to be discontinued. TRELEGY should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
    • Decreases in bone mineral density have been observed with long‐term administration of products containing ICS. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care prior to initiating TRELEGY and periodically thereafter.
    • Glaucoma, increased intraocular pressure, and cataracts have been reported following the long‐term administration of ICS or inhaled anticholinergics. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use TRELEGY long term.
    • Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a healthcare provider immediately if signs or symptoms of acute narrow-angle glaucoma develop.
    • Use with caution in patients with urinary retention, especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if signs or symptoms of urinary retention develop.
    • Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines.
    • Be alert to hypokalemia and hyperglycemia.
    • Orally inhaled corticosteroids may reduce growth velocity in children and adolescents.

    ADVERSE REACTIONS: TRELEGY 100/62.5/25 MCG FOR COPD

    • In subjects with COPD, the most common adverse reactions (≥1% and more common than placebo + FF/VI) reported in two 12-week clinical trials with UMEC + FF/VI, the components of TRELEGY, (and placebo + FF/VI) were: headache, 4% (3%); back pain, 4% (2%); dysgeusia, 2% (<1%); diarrhea, 2% (<1%); cough, 1% (<1%); oropharyngeal pain, 1% (0%); and gastroenteritis, 1% (0%).
    • Additional adverse reactions (≥1% incidence) reported in subjects with COPD taking TRELEGY in a 52-week trial included upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, arthralgia, influenza, sinusitis, pharyngitis, rhinitis, constipation, urinary tract infection, and dysphonia.

    ADVERSE REACTIONS: TRELEGY FOR ASTHMA

    • In subjects with asthma, the most common adverse reactions (≥2% incidence with TRELEGY) reported in a 24-week to 52-week clinical trial with:
      • TRELEGY 100/62.5/25 mcg (or FF/VI 100/25 mcg) were: pharyngitis/nasopharyngitis, 17% (16%); headache, 9% (7%); upper respiratory tract infection/viral upper respiratory tract infection, 5% (7%); respiratory tract infection/viral respiratory tract infection, 4% (4%); bronchitis, 4% (3%); influenza, 4% (3%); back pain, 3% (4%); sinusitis/acute sinusitis, 2% (3%); rhinitis, 2% (3%).
      • TRELEGY 200/62.5/25 mcg (or FF/VI 200/25 mcg) were: pharyngitis/nasopharyngitis, 15% (16%); upper respiratory tract infection/viral upper respiratory tract infection, 7% (6%); headache, 5% (6%); bronchitis, 5% (5%); sinusitis/acute sinusitis, 3% (2%); respiratory tract infection/viral respiratory tract infection, 3% (2%); back pain, 2% (1%); urinary tract infection, 2% (<1%).

    DRUG INTERACTIONS

    • TRELEGY should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval, or within 2 weeks of discontinuation of such agents, because they may potentiate the effect of vilanterol on the cardiovascular system.
    • Use beta‐blockers with caution, as they not only block the pulmonary effect of beta‐agonists, such as vilanterol, but may produce severe bronchospasm in patients with COPD or asthma.
    • Use with caution in patients taking non–potassium-sparing diuretics, as ECG changes and/or hypokalemia associated with these diuretics may worsen with concomitant beta-agonists.
    • Avoid coadministration of TRELEGY with other anticholinergic-containing drugs, as this may lead to an increase in anticholinergic adverse effects.

    USE IN SPECIFIC POPULATIONS

    • TRELEGY is not indicated for use in children and adolescents. The safety and efficacy in pediatric patients (aged 17 years and younger) have not been established.
    • Use TRELEGY with caution in patients with moderate or severe hepatic impairment, as fluticasone furoate systemic exposure may increase by up to 3-fold. Monitor for corticosteroid-related side effects.

    Please see full Prescribing Information, including Patient Information, for TRELEGY.

    To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or 1-888-825-5249 or
    FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Definitions
    COPD=chronic obstructive pulmonary disease; GINA=Global Initiative for Asthma; GOLD=Global Initiative for Chronic Obstructive Lung Disease; ICS=inhaled corticosteroid; LABA=long-acting beta2-adrenergic agonist; LAMA=long-acting muscarinic antagonist; SABA=short-acting beta2-adrenergic agonist; TRELEGY 100=TRELEGY 100/62.5/25 mcg; TRELEGY 200=TRELEGY 200/62.5/25 mcg.

    References

    1. Data on file, GSK. Study 201071.

    2. Data on file, GSK. Study 201594.

    3. Feldman GJ, Galkin DV, Patel P, et al. Correct use and ease of use of a placebo dry powder inhaler in subjects with asthma and chronic obstructive pulmonary disease. Chron Respir Dis. 2019;16:1-10.

    4. Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344(1):218-230. 

    5. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345(2):260-270. 

    6. Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol. 2011;670(1):244-251.

    7. BREZTRI [US package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP, December 2022.

    8. SYMBICORT [US package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP, July 2019.

    9. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025 report. Accessed December 17, 2024. https://goldcopd.org/2025-gold-report/

    10. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2025 report. Accessed May 7, 2025. https://ginasthma.org/reports/

    11. Raissy HH, Kelly HW, Harkins M, Szefler SJ. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med. 2013;187(8):798-803.

    12. Barnes PJ, Burney PGJ, Silverman EK, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:1-21.

    13. Cazzola M, Molimard M. The scientific rationale for combining long-acting ß2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257-267.